On June 6, Xishan Technology, an investee company of Jinhe Capital—a sub-fund backed by the mother fund managed by Yuanhe Chencun—was listed on the STAR Market of the Shanghai Stock Exchange, with stock code: 688576.

Founded in 1999, Xishan Technology specializes in surgical instruments, with a particular focus on minimally invasive surgical devices. The company is primarily engaged in the research and development, manufacturing, and sales of minimally invasive surgical tools. It has developed innovative products such as surgical power systems, endoscopes, and energy-based surgical equipment. Its flagship offerings include complete surgical power units, along with consumables and accessories, designed for cutting, grinding, planing, sawing, milling, and shaping both bone and soft tissues during surgical procedures—especially in minimally invasive surgeries. These advanced tools are widely used across various clinical specialties, including neurosurgery, otolaryngology, orthopedics, and breast surgery.

As a knowledge-intensive, high-tech enterprise, Xishan Technology has always prioritized independent innovation as the cornerstone of its development. As of December 31, 2022, Xishan Technology had secured over 900 patents, obtained 6 Class III national medical device registration certificates, and more than 40 Class II medical device registration certificates. Additionally, the company took the lead in drafting 7 national industry standards for surgical power devices, while also undertaking multiple national and municipal-level scientific research and industrialization projects. These efforts have strongly supported the nation’s strategic technological positioning in the surgical power device sector, contributing significantly to breaking the technological and market monopolies held by foreign manufacturers in this field.

After more than 20 years of hard work and relentless effort, Xishan Technology has become one of the leading enterprises in China's surgical power device industry. Relying on a nationwide marketing network, the company’s products have been sold to nearly 3,000 hospitals, establishing a strong customer base and building significant brand recognition. Xishan Technology We will leverage this STAR Market listing as an opportunity to raise capital, which will be primarily invested in projects such as the industrialization of surgical power systems. Looking ahead, by fully harnessing our independently developed core technologies and capitalizing on our collaborative "industry, academia, research, and medicine" model, we aim to expand our production capacity while simultaneously upgrading our production lines with automation to enhance both efficiency and product quality. This strategic approach will strengthen our market competitiveness and enable us to progressively evolve into a globally competitive provider of comprehensive minimally invasive surgical tool solutions.